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Abstract
Rationale: Cohort studies suggest that airﬂow obstruction is
established early in life, manifests as childhood asthma and wheezy
bronchitis, and continues into early adulthood. Although an
association between childhood asthma and chronic obstructive
pulmonary disease (COPD) in later life has been demonstrated, it is
unclear if childhood wheezy bronchitis is associated with COPD.
Objectives: To investigate whether childhood wheezy bronchitis
increases the risk of COPD in the seventh decade.
Methods:Acohort of children recruited in 1964 at age 10 to 15 years,
whichwas followedup in 1989, 1995, and 2001,was followedup again
in 2014 when at age 60 to 65 years. Discrete time-to-event and linear
mixed effects models were used.
Measurements andMainResults: FEV1 and FVCweremeasured.
COPD was deﬁned as post-bronchodilator FEV1/FVC,0.7.
Childhood wheezing phenotype was related to 1989, 1995, 2001, and
2014 spirometry data. Three hundred thirty subjects, mean age
61 years, were followed up: 38 with childhood asthma; 53 with
childhoodwheezy bronchitis; and 239 control subjects (of whom 57
developed adulthood-onset wheeze between ages 16 and 46 yr). In
adjusted multivariate analyses, childhood asthma was associated
with an increased risk of COPD (odds ratio, 6.37; 95%
conﬁdence interval, 3.73–10.94), as was childhood wheezy
bronchitis (odd ratio 1.81; 95% conﬁdence interval, 1.12–2.91). The
COPD risk increased with childhood asthma, and wheezy
bronchitis was associatedwith reduced FEV1 thatwas evident by the
ﬁfth decade and not an accelerated rate of FEV1 decline. In contrast,
adulthood-onset wheeze was associated with accelerated FEV1
decline.
Conclusions: Childhood wheezy bronchitis and asthma are
associated with an increased risk of COPD and reduced ventilatory
function.
Keywords: childhood wheezing phenotypes; asthma; chronic
obstructive pulmonary disease; pulmonary function decline
Chronic obstructive pulmonary disease
(COPD) is a major cause of morbidity and
mortality worldwide (1). In the United
Kingdom, approximately 900,000 people
have diagnosed COPD, with an estimated
additional 2 million people being
undiagnosed (2). COPD is the ﬁfth leading
cause of death, accounting for approximately
30,000 deaths annually (3, 4), and is a
leading cause of emergency hospitalization
(5). In developed countries, cigarette
smoking is the major risk factor for COPD;
however, additional factors are important
because the population attributable fraction
for smoking is ,80% (6), and only a
minority (10–20%) of smokers develop
clinically signiﬁcant disease (7).
Many preschool children (20% by 6 yr)
develop wheezing symptoms (wheezy
bronchitis/virus-associated wheeze [WB/
VAW]) during episodes of viral respiratory
tract infection, but they are asymptomatic
thereafter (8). Epidemiological ﬁndings
suggest that childhood WB/VAW and
COPD may be closely associated (9),
because both are the consequence of an
underlying abnormality of airway
development characterized by reduced
ventilatory function in early life and
possibly accelerated ventilatory function
decline in later life. Studies have reported
associations between childhood records of
lower respiratory tract infection and
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reduced FEV1 or COPD during adulthood
(10, 11). Birth cohort studies have
demonstrated tracking of ventilatory
function with reduced neonatal/infant
ventilatory function being associated with
WB/VAW, childhood asthma (CA),
reduced FEV1, and airﬂow obstruction up
to age 22 years (8, 12–14). Addressing the
issue of whether WB/VAW increases
COPD risk requires a prospective study
that relates childhood WB/VAW to
ventilatory function in middle/old age. The
Melbourne Asthma Study (MAS) recruited
484 children aged 7 years based on
wheezing/asthma status in 1964 and
measured ventilatory function at age 50
years. Although CA was associated with
COPD, WB/VAW was not (15, 16).
The Aberdeen WHEASE (What
Happens Eventually to Asthmatic children:
Sociologically and Epidemiologically)
cohort of children recruited in 1964 is
similarly placed to investigate whether
WB/VAW increases the risk of COPD.
Follow-up of this cohort in 2001, when the
subjects were aged 47 to 52 years,
demonstrated that childhood WB/VAW
was associated with an increased rate of
FEV1 decline that, if sustained, could
result in COPD (17–20). We report the
50-year follow-up of the WHEASE cohort
to test the hypothesis that childhood WB/
VAW increases the risk of COPD in the
seventh decade of life. The study was also
able to investigate the effects of CA and
adult-onset wheeze (AOW) on the risk of
COPD.
Methods
WHEASE Cohort
In 1964, a random 20% sample of
Aberdeen schoolchildren aged 10 to 15
years (n = 2511), reported that 288 children
had “ever had a wheezy chest” (18). After a
pediatrician reviewed primary and
secondary care medical records, and
conducted a face-to-face clinical
assessment, 121 children were classiﬁed as
having CA (recurrent dyspnea of an
obstructive type without demonstrable
cause), and 167 were classiﬁed as having
WB (wheeze only in the presence of
upper respiratory tract infection). The
remaining 2223 children had no respiratory
symptoms (control subjects). Childhood
spirometry was recorded for subjects with
asthma and WB/VAW, but was not
recorded in control subjects. In 1989, when
the subjects were aged 35 to 40 years,
ventilatory function was measured in 72
subjects with CA, 107 with WB, and a
random sample of 93 control subjects (20).
In 1995, at age 41 to 46 years, in a cluster
case–control study, ventilatory function
was measured in 212 control subjects and
100 subjects who had developed wheeze
between 16 and 46 years; these subjects
were classiﬁed as having AOW (17). In
2001, at age 47 to 52 years, subjects from
WHEASE-1989 and -1995 were contacted,
and ventilatory function was measured in
46 subjects with CA, 65 subjects with
WB/VAW, 57 subjects with AOW, and
213 control subjects (19).
In 2014, all participants of WHEASE-
1989, -1995, and -2001 were invited to
participate in the fourth follow-up.
Assessments and Outcomes
Assessments were identical to WHEASE-
2001 (19). A researcher administered the
same modiﬁed version of the Medical
Research Council questionnaire (21) to
assess respiratory health, medication, and
smoking status. Spirometry was performed
according to American Thoracic Society
(ATS)/European Respiratory Society (ERS)
standards (22) using a Vitalograph
Compact II spirometer (Vitalograph,
Buckingham, United Kingdom).
Spirometry was performed before and
15 minutes after administration of 400-mg
albuterol, and the following parameters
were recorded: FEV1, FVC, and forced
expiratory ﬂow at 25% to 75% of FVC
(FEF25–75%). The study was approved by the
North of Scotland Research Ethics Service
(13/NS/0038), and participants provided
written informed consent.
Statistical Analysis
The primary outcome was COPD as deﬁned
by the Global Initiative for Chronic
Obstructive Lung Disease (post-
bronchodilator FEV1/FVC ,0.7) (23).
Analyses were repeated using an alternative
deﬁnition (post-bronchodilator FEV1/FVC
less than the lower 95% conﬁdence limit of
the internationally agreed predictive
equations for normality (LLN)] (22, 24).
Pediatric spirometry was adjusted for sex,
age, and height referenced to a modern
standard (25). Adult spirometric indexes
were expressed as the percent predicted as
deﬁned by the ERS Global Lung Function
Initiative 2012 (24). The primary
explanatory variable of interest was the
original 1964 childhood wheeze category
(i.e., subjects with CA, subjects with
WB/VAW, and control subjects) (18).
Additional analyses used the WHEASE-
2001 categories: subjects with CA; subjects
with WB/VAW; control subjects; and
subjects with AOW, which included
childhood control subjects who developed
wheeze between 16 and 46 years. The
Scottish Index of Multiple Deprivation
(SIMD) (26) quintile scores were used as
the metric of socioeconomic status (SES).
SIMD is an area-based measure of
deprivation based on residential postal
code, with the ﬁrst quintile being the most
deprived.
Univariate comparisons between
WHEASE-2014 participants stratiﬁed by
wheezing category used the x2 test,
Student’s t test, or analysis of variance,
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: The outcome in later life of
childhood wheezing illness conﬁned to
viral respiratory tract infections
(wheezy bronchitis/viral associated
wheeze [WB/VAW]) is unknown.
Recent birth cohort studies suggest
tracking of suboptimal lung function
from birth is associated with WB/
VAW and predict WB/VAW to be
associated with an increased risk of
chronic obstructive pulmonary disease
(COPD) in later life. A previous
longitudinal study spanning 50 years
demonstrated that childhood asthma,
but not WB/VAW, was associated with
COPD in later life.
What This Study Adds to the
Field: This 50-year cohort study has
followed children to the oldest age of
any of the existing cohorts to date. This
study has shown for the ﬁrst time that
childhoodWB/VAW is associated with
an increased risk of COPD and reduced
lung function in the seventh decade.
This ﬁnding should lead to a re-
evaluation of the advice given to
children with WB/VAW and their
parents, of the increased risk of COPD
and the need to avoid additional risk
factors such as smoking. Later-life
monitoring of ventilatory functionmay
be deemed appropriate.
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using Bonferroni adjusted P values for
between-group differences. Logistic
regression was used to relate COPD status
at WHEASE-2014 with childhood wheezing
phenotype with adjustment for sex, age in
2014, smoking history, and SES. Two
methods (27) were used to relate childhood
wheezing phenotype to all ventilatory
function data collected during WHEASE-
1989, -1995, -2001, and -2014. A discrete
time to event (COPD) model was used to
assess differences between groups, with
adjustment for sex, age, smoking history,
and SES. Linear mixed effect models were
used to analyze repeated FEV1 over time.
All participants were included, and any
missing FEV1 data were assumed to be
missing at random. The model was ﬁtted
with unstructured covariance to account for
the correlated measurements (within a
person). The models were adjusted for age
in 1989, sex, smoking, height, and SES.
Time was entered into the model taking the
values of 0, 6, 12, and 25 years to represent
assessments made in 1989, 1995, 2001, and
2014. Inclusion of an interaction term for
time and wheezing group allowed the
production of estimates of change in FEV1
between groups. Analyses were performed
using SPSS (version 22.0; IBM, Armonk,
New York) and SAS (version 9.3; SAS
Institute Inc., Cary, NC).
Sample Size
We estimated that 80% of the 381
WHEASE-2001 (19) participants would
participate in WHEASE-2014. Based on
WHEASE-2001, with 304 participants (52
subjects with WB/VAW, 37 subjects with
CA, and 215 control subjects), and a 12%
prevalence of COPD in control subjects
(a = 0.05), the study would have 80% power
to detect a 2.3-fold change in COPD risk
associated with WB/VAW (i.e., control
subjects 12%, subjects with WB/VAW
28%).
Results
Three hundred thirty people with a mean6
SD age 60.76 1.5 years participated in
WHEASE-2014. Table 1 compares details
of those who did or did not take part;
nonparticipants were more likely to have a
history of smoking. Figure 1 summarizes
the participant details throughout the
50 years of this study. Of the 330
participants, 262 had also participated in
WHEASE-2001, and the remaining 68
participated in WHEASE-1989 and/or
-1995. Based on the original 1964
classiﬁcation, 38 of WHEASE-2014
participants had had CA, 53 participants had
WB/VAW, and 239 were control subjects;
using the WHEASE-2001 classiﬁcation,
there were 38 subjects with CA, 53 subjects
with WB/VAW, 57 subjects with AOW, and
182 control subjects. Participant
characteristics as deﬁned by the 1964 and
2001 wheezing categories are presented in
Table 2. Compared with control subjects,
those with CA and WB/VAW were more
likely to be men (P = 0.03 and P = 0.023,
respectively), those with WB/VAW were
from less deprived areas (P = 0.013), and
subjects with AOW were from more
deprived areas (P = 0.013). Also, compared
with controls, participants with WB/VAW
were more likely to have been diagnosed
with asthma (P = 0.023), whereas subjects
with AOW were more likely to have been
diagnosed with COPD (P, 0.001) or
asthma (P, 0.001).
The mean6 SD percentage predicted
FEV1/FVC in childhood (mean age, 12.3 yr)
was 89% (19) for the 35 subjects with CA
and 100% (8) for 43 subjects with WB/
VAW, (P = 0.001), and the corresponding
mean percent predicted FEV1 values were
90 (21) and 101 (13) (P = 0.007). After
adjustment for sex and height, children
with CA had a mean reduction in the FEV1/
FVC ratio of 0.08 (95% conﬁdence
interval [CI], 0.04–0.11) compared with
WB/VAW (P, 0.001), and for FEV1, the
mean reduction was 267 ml (range, 0–536)
(P = 0.052).
Childhood Wheezing Phenotype and
COPD Status at 60 to 65 Years
COPD status and ventilatory function at age
60 to 65 years are shown in Table 3. In
univariate analyses, compared with control
subjects, adults with CA had reduced FEV1,
FVC, FEF25–75%, FEV1/FVC, and were
more likely to have COPD at ages 60 to
65 years when deﬁned as FEV1/FVC ,0.7
or less than LLN (Bonferroni adjusted P,
0.001–0.012). Compared with controls,
subjects with AOW, as deﬁned in
WHEASE-2001, had reduced FEV1/FVC
(Bonferroni adjusted P = 0.045).
The results of multivariate analysis
relating childhood wheezing phenotype to
COPD status at age 60 to 65 years are
presented in Table 4. CA was associated
with COPD when expressed as FEV1/FVC
,0.7 or less than LLN, but WB/VAW was
not. AOW was associated with COPD
when deﬁned as less than LLN (P = 0.05). A
history of ever smoking was associated with
COPD, with odds ratios of typically 3.0 to
3.5; sex and SES were not associated with
COPD.
Childhood Wheezing Phenotype and
All WHEASE Ventilatory Function Data
35 to 65 Years
The 1964 and 2001 wheeze groupings were
related to spirometry data collected in
WHEASE-1989, -1995, -2001, and -2014.
The results of the time-to-event analysis are
presented in Table 5. CA was associated
with COPD, which was deﬁned as FEV1/
FVC ,0.7 or less than LLN (P, 0.001).
Based on the 1964 classiﬁcation, WB/VAW
was associated with COPD, which was
deﬁned as FEV1/FVC ,0.7 (P = 0.034).
Repeating the analysis using the 2001
classiﬁcation demonstrated that WB/VAW
was associated with COPD when deﬁned as
FEV1/FVC ,0.7 (P = 0.015). AOW was
Table 1. Details of Participants Who Did or Did Not Take Part in WHEASE 2014
Nonparticipants (n = 253) Participants (n = 330)
Sex, male, n (%) 122 (48.2) 171 (51.8)
Age, yr, mean (SD) 60.8 (1.4) 60.7 (1.5)
Ever smoker, n (%) 158 (63.7) 168 (50.9)*
Wheeze category (based on 2001)
Childhood asthma, n (%) 34 (13.5) 38 (11.5)
Childhood wheezy bronchitis, n (%) 53 (21.0) 53 (16.1)
Adult-onset wheeze, n (%) 40 (15.9) 57 (17.3)
Control, n (%) 125 (49.6) 182 (55.2)
Definition of abbreviation: WHEASE =What Happens Eventually to Asthmatic children: Sociologically
and Epidemiologically.
Smoking and wheeze category data missing for 5 and 1 nonparticipants, respectively.
*P = 0.002.
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also associated with COPD when deﬁned as
FEV1/FVC less than LLN (P = 0.019).
The results of the linear mixed effects
modeling to assess trends in FEV1 between
1989 and 2014 are presented in Table 6. For
those with no wheeze in childhood
(i.e., childhood control subjects), the average
annual decline in FEV1 was 34 ml (95% CI,
32–37), and for those with no wheeze
reported in childhood or adulthood, the
average decline was 33 ml/annum (95% CI,
30–36). Based on the 1964 wheeze
phenotypes, compared with control subjects,
the mean FEV1 of participants with CA was
560 ml lower (95% CI 400–720), and the
mean FEV1 of subjects with WB/VAW was
190 ml lower (95% CI, 50–320). However,
the rate of FEV1 decline did not differ
between the 1964 wheeze groups.
Repeating this model to include
subjects with AOW demonstrated similar
associations with those with CA and WB/
VAW as previously described. However,
compared with control subjects, the FEV1
of subjects with AOW was no different
(P = 0.573), but the rate of FEV1 decline
was greater by 9 ml/yr (95% CI, 2–16;
P = 0.008).
Discussion
For the ﬁrst time, we demonstrated in a
prospective longitudinal study that children
with a history of WB/VAW are more likely
to develop COPD from the ﬁfth decade
onwards. This is likely because of the
tracking of reduced FEV1, which is evident
by the ﬁfth decade, and not the increased
rate of FEV1 decline. Although childhood
wheezy bronchitis was not associated with
COPD when related to ventilatory function
data collected at WHEASE-2014 (ages
60–65 yr), an association was evident when
related to ventilatory function data
collected during the four phases of
WHEASE follow-up (ages 35–65 yr), which
afforded greater power. Children with
asthma already had obstructive spirometry
compared with WB/VAW by the age of 10
to 15 years, and were also more likely to
develop COPD from the fourth decade
onwards. However, this was not a
consequence of an increased rate of FEV1
decline, but was due to preservation of
reduced FEV1 from childhood. A further
novel ﬁnding was that adults who
developed wheezing illness between the
ages of 16 and 46 years were at increased
risk of COPD from the ﬁfth decade onward
because of the increased rate of FEV1
decline.
The analysis and present ﬁndings from
the fourth WHEASE follow-up differed
from previous studies because COPD as
deﬁned by the FEV1/FVC ratio was the
primary outcome; previous WHEASE
studies reported FEV1 and rate of FEV1
decline as outcomes. Furthermore, this was
the ﬁrst time that all spirometry data from
all subjects in all phases of WHEASE
follow-up from 1989 to 2014 were included
in single models. WHEASE-1989 (20)
reported that at ages 35 to 40 years,
compared with controls, the percent of
predicted FEV1 of CA (but not WB/VAW)
was reduced. In the present study, with the
greater power afforded by the analysis of all
the data collected in the four follow-up
phases of WHEASE (ages 35–65 yr), the
FEV1 of subjects with CA and WB/VAW
was signiﬁcantly reduced compared with
control subjects. WHEASE-2001 (19)
reported FEV1 differences between control
subjects and subjects with CA (510 ml) and
subjects with WB/VAW (180 ml) that were
very similar to those we reported of 560 and
200 ml, respectively. Consistent with the
difference in adult FEV1 between CA and
WB/VAW, we reported a mean difference
in FEV1 of 267 ml at age 12 years between
these groups. In the present study, we
reported no differences in the rate of FEV1
decline among subjects with CA, subjects
with WB/VAW, and control subjects,
whereas in WHEASE-2001, between 1989
and 2001, the rate of FEV1 decline of
subjects with CA (65 ml/yr) and subjects
with WB/VAW (65 ml/yr) was greater than
that of control subjects (15 ml/yr). This
disparity probably reﬂects the 2001 analysis
being restricted to subjects with paired 1989
and 2001 data, such that only 66 control
subjects were included; the present analysis
included data from 239 control subjects
spanning from 1989 and 1995 to 2014.
Although asthma in early adulthood
has been linked to lung function in later life
(28), WHEASE is one of a handful of cohort
583 (WHEASE 1989, 1995, 2001
participants) contacted
330 participated including 38 CA,
53 WB and 239 C (including 57 AOW):
Questionnaire n 328
Spirometry n 329
Deceased n 14
Declined to take part n 28
No response n 148
Untraceable n 63
2743 contacted, 2511 participated including
121 childhood asthma (CA), 167 wheezy
bronchitis (WB) and 2223 controls (C)
Spirometry measured in 288
Recruitment 1964
Age 10–15 years
455 contacted, 360 participated including
97 CA, 132 WB and 131 C
Spirometry measured in 272
WHEASE-1989
Age 35–40 years
1758 contacted, 1542 participated
(all C, but now including 177 adult onset
wheeze, AOW) Spirometry measured in 312
WHEASE-1995
Age 41–46 years
605 contacted, 381 participated including
46 CA, 65 WB and 270 C (including 57 AOW)
Spirometry measured in 381
WHEASE-2001
Age 47–52 years
WHEASE-2014
Age 58–64 years
Figure 1. Consolidated Standards of Reporting Trials–style diagram showing the number of
individuals invited to participate and the number of participants, including the number in whom
lung function was available and the number in each of the wheezing categories.
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studies able to relate CA and WB/VAW to
COPD in middle/old age. MAS recruited
484 children aged 7 years in 1964, followed
them up every 7 years, and recently
reported follow-up at mean age 51.4 years.
The present study conﬁrms the ﬁnding by
MAS (16) that CA is associated with an
increased risk of COPD at age 51 years, and
that there is no difference in the rate of
FEV1 decline of CA, WB/VAW, and in
control subjects in adulthood. We also
replicated the MAS observation that the
FEV1 difference between CA and WB/
VAW is established in childhood. We were
able to extend the MAS observations by
demonstrating, for the ﬁrst time, that
WB/VAW is associated with an increased
risk of COPD in adulthood. The older age of
follow-up in WHEASE-2014 (mean 61 yr)
compared with MAS (mean age 51 yr), the
greater number of subjects, in particular
control subjects, with FEV1 data at this age in
WHEASE-2014 (329 subjects with 239
control subjects) compared with MAS (197
subjects with 48 control subjects) might have
contributed to our detecting a modest
increased COPD risk among subjects with
WB/VAW. Follow-up of the British
1958 (29) birth cohort also reported that
childhood wheezing illness was not associated
with an increased rate of FEV1 decline in
adults between 35 and 45 years of age,
although the age of follow-up was somewhat
younger than that in WHEASE-2014 or
MAS.
The present study and MAS gave
important insights into the natural history of
obstructed lung function from childhood to
later life. The ﬁrst insight of a link between
respiratory outcomes in early and later life
came from the observation of correlations
betweenmortality rates from infant and adult
respiratory causes within geographic areas
(30). Tracking of suboptimal ventilatory
function was demonstrated in the Tucson
cohort, in which reduced ventilatory
function at 2.3 months was associated with a
reduced FEV1/FVC ratio and reduced
FEV1 up to age 22 years (12). A study of
similar design in Australia also observed
associations between reduced ventilatory
function at 1 month and reduced ventilatory
function in 18 year olds (13). These studies
suggest that early life factors program airway
development, such that reduced ventilatory
function is established very early in the life
course and tracks up to the age of 22 years.
The positive association between fetal size at
10 weeks’ gestation and FEV1 in 10 year olds
suggests that the factors determining lung
function trajectory are already active at a
very early developmental stage (31). A
consequence of such tracking is that infants
and children with reduced ventilatory
function would be more likely to have the
same reduced FEV1/FVC ratio as adults.
Although WHEASE and other studies have
demonstrated that this is the case for CA,
WHEASE has now conﬁrmed that
childhood WB/VAW is also associated with
an increased risk of COPD in later life.
Although we were not able to compare
childhood lung function between subjects
with WB and control subjects, our
ﬁndings suggest that lung function among
those with WB was not obviously abnormal
in childhood, when standardized to a
modern reference population, but during
adulthood those with WB were at
increased risk of obstructed lung function,
independent of confounders. Our
observations support the paradigm that
CA is linked to COPD by an airway
developmental abnormality present from
childhood. However, the association
between WB and COPD may be by a
different mechanism that affects the
airways, or by the same mechanism but
which is of lesser magnitude and/or acting
later in life.
Table 2. Characteristics of 330* WHEASE 2014 Participants by 1964 and 2001 Wheezing Phenotype Categories
Total
(n = 330)
1964 Deﬁnitions 2001 Deﬁnitions (Including AOW)
CA†
(n = 38)
WB/VAW‡
(n = 53)
Controlsx
(n = 239)
AOW
(n = 57)
Controls||
(n = 182)
Male, n (%) 171 (51.8) 25 (65.8) 34 (64.2) 112 (46.9)¶ 31 (54.4) 81 (44.5)¶
Age, yr, mean (SD) 60.7 (1.5) 60.6 (1.5) 60.9 (1.6) 60.6 (1.5) 60.9 (1.5) 60.5 (1.5)
BMI, kg/m2, mean (SD) 28.8 (5.8) 30.4 (7.9) 29.6 (5.4) 28.4 (5.5) 29.3 (6.39) 28.2 (5.19)
Smoking ever, n (%) 168 (50.9) 20 (52.6) 23 (43.4) 125 (52.3) 35 (61.4) 90 (49.5)
SIMD quintile, median (IQR) 4 (3–5) 4.5 (3–5) 5 (3–5) 4 (2–5)¶ 4 (2–5) 4 (2.5–5)¶
Dyspnea (MRC score >1), n (%) 76 (26.8) 11 (37.9) 12 (26.1) 53 (25.4) 18 (39.1) 35 (21.5)
Chesty cough most days, n (%) 46 (14.0) 8 (21.1) 6 (11.3) 32 (13.5) 13 (22.8) 19 (10.6)
Phlegm most days, n (%) 47 (14.3) 11 (28.9) 6 (11.3) 30 (12.7)** 12 (21.1) 18 (10.0)¶
Wheeze last 12 mo, n (%) 69 (21.0) 20 (52.6) 8 (15.1) 41 (17.2)** 22 (38.6) 19 (10.5)
Asthma diagnosis, n (%) 77 (23.4) 31 (81.6) 11 (20.8) 35 (14.7)†† 24 (42.1) 11 (6.1)††
COPD diagnosis, n (%) 18 (5.5) 3 (7.9) 0 (0.0) 15 (6.3) 10 (17.5) 5 (2.8)††
Inhalers prescribed, n (%) 70 (21.3) 27 (71.1) 5 (9.4) 38 (16.0)†† 20 (35.1) 18 (9.9)††
Definition of abbreviations: AOW= adult-onset wheeze; BMI = body mass index; CA = childhood asthma; COPD= chronic obstructive pulmonary
disease; IQR = interquartile range; MRC=Medical Research Council; SIMD = Scottish Index of Multiple Deprivation; WB/VBW=wheezy bronchitis/
virus-associated wheeze; WHEASE =What Happens Eventually to Asthmatic children: Sociologically and Epidemiologically.
*Questionnaire data in 328 subjects and physiological measurements in 329 subjects.
†Childhood asthma.
‡Childhood WB/VAW.
xChildhood controls.
||Adult controls. In these columns, the individuals with AOW who were defined as controls in 1964 are compared with subjects who never developed
respiratory symptoms.
¶P, 0.02 for differences across childhood groups by one-way analysis of variance and x2 tests.
**P, 0.03 for differences across childhood groups by x2 test.
††P, 0.001 for differences across childhood groups by x2 test.
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Although the initial assessment of
cohort members took place at age 10 to
15 years, there is reliable evidence of very
early onset of symptoms among those with
CA, whom we described as already having
reduced FEV1 as children and being at
highest risk for COPD at ages 60 to 65
years. As part of the initial assessment of
this cohort, the primary and secondary care
medical notes of the subset with CA were
examined, and 44% had onset of symptoms
by 2 years of age and 81% by 5 years of age
(18). Therefore, we can be conﬁdent in the
age at onset of symptoms in those with CA.
Although we are conﬁdent that the clinical
assessment of the children with wheezy
bronchitis was just as thorough, because of
the asthma focus of the original study, the
age of onset of wheezy bronchitis was not
published. Despite clinical diligence, it is
possible that some subjects with AOW may
have had a history of transient wheeze in
early childhood that was not reported or
recalled by parents when their child was
aged 10 to 15 years; this phenomenon has
been previously described (12). Such
misclassiﬁcation of children who wheezed
as “controls” is a null bias likely to
attenuate any association between WB/
VAW and COPD. When subjects with
AOW are removed from the childhood
control group, there is a marginal increase
in risk for COPD among those with
wheezy bronchitis (Table 5), but there is
no difference in change in lung function
(Table 6). This suggests that unreported
latent/transient childhood wheeze that
recurred in later life has not substantially
affected our results. This was not a
birth cohort study, and our study design, in
which symptom status is unknown for
early childhood (except the CA group),
may lead to misclassiﬁcation of
phenotypes. This is a weakness that we
acknowledge. However, misclassiﬁcation
of WB/VAW children as control subjects
is likely to attenuate any association
between WB/VAW and COPD (i.e., a
null bias).
In WHEASE-1995, 177 (11.5%) of
1542 control subjects had developed
wheeze between 16 to 46 years of age (17).
In the present study, these subjects with
AOW had an increased risk of developing
Table 4. Associations between 1964 and 2001 Wheezing Groups and Chronic
Obstructive Pulmonary Disease at Ages 60 to 65 Years: Results of Logistic Regression
Analysis
FEV1/FVC < 0.7
[Adjusted OR* (95% CI)]
FEV1/FVC < LLN
[Adjusted OR* (95% CI)]
1964 wheeze groups
Childhood controls, n = 239 1.00 1.00
Childhood asthma, n = 38 4.39 (1.98–9.73) 5.29 (2.46–11.4)
Childhood WB/VAW, n = 53 1.36 (0.71–2.63) 1.39 (0.67–2.89)
2001 wheeze groups
Childhood controls, n = 182 1.00 1.00
Childhood asthma, n =38 4.90 (2.18–11.0) 6.42 (2.90–14.2)
Childhood WB/VAW, n = 53 1.52 (0.77–2.99) 1.67 (0.79–3.60)
Adult-onset wheeze
(16–45 yr), n = 57
1.56 (0.82–2.96) 1.97 (1.00–3.91)
Definition of abbreviations: CI = confidence interval; OR = odds ratio; LLN = lower 95% confidence
limit of the internationally agreed predictive equations for normality; WB/VBW=wheezy bronchitis/
virus-associated wheeze.
*Adjusted for sex, age, history of ever smoking, and Scottish Index of Multiple Deprivation in 2014.
Table 3. Ventilatory Function Characteristics in WHEASE 2014 by 1964 and 2001 Wheezing Phenotype Categories
Total (n = 330)*
1964 Deﬁnitions 2001 Deﬁnitions (Including AOW)
CA† (n = 38)
WB/VAW‡
(n = 53)
Controlsx
(n = 239) P Value AOW (n = 57)
Controls||
(n = 182) P Value
FEV1, %pred,
mean (95%CI)
95.5 (93.4–97.3) 81.3 (72.8–89.9) 97.3 (93.2–101.4) 97.1 (95.1–99.2) ,0.001¶ 92.5 (88.0–97.0) 98.6 (96.3–101) ,0.001¶
FVC, %pred,
mean (95%CI)
107 (106–109) 100 (94.4–106) 108 (104–112) 108 (106–110) 0.014¶ 107 (102–112) 108 (106–110) 0.025¶
FEF25–75%,%pred,
mean (95%CI)
76.1 (72.2–79.9) 55.9 (43.7–68.1) 83.1 (72.4–93.8) 77.8 (73.5–82.1) 0.001¶ 67.3 (59.1–75.5) 81.1 (76.1–86.1) ,0.001¶
FEV1/FVC,
mean (95%CI)
0.69 (0.68–0.70) 0.62 (0.58–0.66) 0.71 (0.68–0.73) 0.70 (0.69–0.71) ,0.001¶ 0.68 (0.66–0.70) 0.71 (0.70–0.73) ,0.001¶
FEV1/FVC
, 0.7, n (%)
143 (43.3) 27 (71.1) 23 (43.4) 93 (38.9) 0.001** 29 (50.9) 64 (35.2) ,0.001**
FEV1/FVC
, LLN, n (%)
100 (30.3) 23 (60.5) 14 (26.4) 63 (26.4) ,0.001** 21 (36.8) 37 (20.3) ,0.001**
Definition of abbreviations: %pred = percentage predicted; AOW= adult-onset wheeze; CI = confidence interval; LLN = lower 95% confidence limit of the
internationally agreed predictive equations for normality; WB/VBW=wheezy bronchitis/virus-associated wheeze; WHEASE =What Happens Eventually to
Asthmatic children: Sociologically and Epidemiologically.
*Questionnaire data in 328 subjects and physiological measurements in 329 subjects.
†Childhood asthma.
‡Childhood WB/VAW.
xChildhood controls.
||Adult controls. When applying the 2001 definitions, spirometry at ages 60 to 65 years is compared only between individuals with AOW (i.e., who were
defined as controls in 1964) and subjects who never developed respiratory symptoms.
¶Difference across childhood groups: one-way analysis of variance.
**Difference across childhood groups: x2.
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COPD. This was related to a more
rapid decline in FEV1 than control
subjects and was not due to having
previously lower FEV1, which suggested
that extrinsic environmental or
occupational factors may play an
important role.
The strengths and limitations of the
present study are a consequence of the
design and focus of previous WHEASE
phases. As an unselected community-based
cohort, the study provides widely
generalizable results. Although the 50-year
follow-up is the same as MAS, our age of
follow-up has been the oldest of any study to
date, with participants being 10 years older
than those in MAS. Clinical assessment of
the children at age 10 to 15 years by an
experienced pediatrician. complemented
with spirometry and review of medical notes
in symptomatic subjects instead of total
reliance on questionnaire responses is
another strength. The main limitation of
the present study is the restriction of
sample size by historical precedent. The
power to detect an association between
WB/VAW and COPD was based on
WHEASE 2001, and although we exceeded
the follow-up target, post hoc analysis
demonstrated that the study was
underpowered to detect an association
between WB/VAW and COPD in
WHEASE-2014 data, because the
prevalence of FEV1/FVC ,0.7 in the
control group was 35% and not 12%, as
in WHEASE-2001 (19). Participant
assessment in WHEASE-2014 was
identical to previous phases of WHEASE,
except for spirometry, which was
conducted post-bronchodilator. Previous
WHEASE studies could have
overestimated the prevalence of FEV1/
FVC ,0.7; however, this does not
appear to have been the case, because
comparison of WHEASE-2001 and -2014
demonstrated that although 20% of
participants transitioned from FEV1/FVC
>0.7 to FEV1/FVC ,0.7, only 2% changed
from FEV1/FVC ,0.7 to FEV1/FVC >0.7.
Fifty-eight percent of those invited to
participate had spirometric assessment as
part of the most recent assessment of this
cohort, and it is highly unlikely that
incomplete participation introduced
selection bias that might create a
false positive ﬁndings, because we
demonstrated that, with the exception
of under-representation of smokers,
the participants were similar to
nonparticipants. Because of the association
between smoking and respiratory
morbidity, this will diminish and not
exaggerate the associations reported
herein.
This is the ﬁrst study to follow children
with wheeze into their seventh decade.
Childhood WB/VAW increased the risk of
COPDandwas associated with reduced FEV1
evident by the ﬁfth decade. Previous studies
suggest that this occurs very early in life,
possibly in utero. This has implications for
the long-term management of children who
develop WB/VAW. We have also conﬁrmed
that CA is associated with an increased risk
of COPD and shown that AOW results in
more rapid decline in ventilatory function. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
Table 6. Linear Mixed-Effects Modeling Applied to all FEV1 Data Collected between
1989 and 2014, Estimates of Group Difference in FEV1 Based on 1964 and 2001
Classiﬁcations
FEV1
Estimate* (95% CI) P Value
1964 wheeze groups
Overall: childhood controls vs. CA, L 20.56 (20.72 to 20.40) ,0.001
Overall: childhood controls vs. WB/VAW, L 20.19 (20.32 to 20.05) 0.008
Difference in decline: childhood
control vs. CA, L/yr
0.0001 (20.005 to 0.007) 0.726
Difference in decline: childhood
control vs. WB/VAW, L/yr
0.002 (20.003 to 0.007) 0.453
2001 wheeze groups
Overall: childhood controls vs. CA, L 20.56 (20.72 to 20.40) ,0.001
Overall: childhood controls vs. WB/VAW, L 20.18 (20.32 to 20.04) 0.028
Overall: childhood controls vs. AOW, L 20.04 (20.11 to 0.20) 0.573
Difference in decline: childhood
controls vs. CA, L/yr
20.0008 (20.007 to 0.007) 0.817
Difference in decline: childhood
control vs. WB/VAW, L/yr
0.0002 (20.005 to 0.006) 0.935
Difference in decline: childhood
control vs. AOW, L/yr
20.009 (20.016 to 20.002) 0.008
Definition of abbreviations: AOW= adult-onset wheeze; CA = childhood asthma; CI = confidence
interval; WB/VBW=wheezy bronchitis/virus-associated wheeze.
n = 1,144 records analyzed.
*Adjusted for sex, age, history of ever smoking, and Scottish Index of Multiple Deprivation in 2014.
Table 5. Associations between 1964 and 2001 Wheezing Groups and Chronic
Obstructive Pulmonary Disease at Ages 35 to 65 Years: Discrete Time Logistic Model
Using All Data Collected between 1989 and 2014
FEV1/FVC < 0.7
[Adjusted OR* (95% CI)]
FEV1/FVC < LLN
[Adjusted OR* (95% CI)]
1964 wheeze groups
Childhood controls, n = 820 1.00 1.00
Childhood asthma, n = 135 5.79 (3.44–9.73) 5.68 (3.41–9.44)
Childhood WB/VAW, n = 189 1.65 (1.04–2.61) 1.56 (0.94–2.59)
2001 wheeze groups
Childhood controls, n = 637 1.00 1.00
Childhood asthma, n = 135 6.37 (3.73– 10.9) 5.11 (2.93–8.92)
Childhood WB/VAW, n = 189 1.81 (1.12–2.91) 1.48 (0.86–2.57)
Adult-onset wheeze
(16–45 yr), n = 183
1.45 (0.91–2.32) 1.86 (1.11–3.13)
Definition of abbreviations: CI = confidence interval; LLN = lower 95% confidence limit of the
internationally agreed predictive equations for normality; OR = odds ratio; WB/VBW=wheezy
bronchitis/virus-associated wheeze.
*Adjusted for sex, age, history of ever smoking, and Scottish Index of Multiple Deprivation in 2014.
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